Hypoxia-inducible factor-1α/β (HIF-1α/β) is a heterodimeric transcriptional activator that mediates gene expression in response to hypoxia. HIF-1α has been noted as an effective therapeutic target for ischemic diseases such as myocardiac infarction, stroke and cancer. By using a yeast two-hybrid system and a random peptide library, we found a 16-mer peptide named F29 that directly interacts with the bHLH-PAS domain of HIF-1α. We found that F29 facilitates the interaction of the HIF-1α/β heterodimer with its target DNA sequence, hypoxia-responsive element (HRE). 
INTRODUCTION
Cells adapt to an hypoxic environment by inducing several types of genes involved in angiogenesis, erythropoiesis and glycolysis (1) . This increase in gene transcription cause by hypoxia is mediated via common cis-acting elements called hypoxia-responsive elements (HREs) (2) . Putative trans-acting factors specific for HREs have been purified and named HypoxiaInducible Factor-1 (HIF-1) α and β. HIF-1β is identical to the previously known protein aryl hydrocarbon receptor nuclear translocator (Arnt). Both HIF-1α and HIF-1β contain basic helix-loop-helix (bHLH) and PAS domains in their N-terminal regions, both of which mediate heterodimerization between the HIF-1α and β subunits. Heterodimerization juxtaposes two basic regions, therefore enabling individual basic regions to contact specific corresponding DNA sequences. Thus, dimerization of bHLH-PAS proteins is a prerequisite for DNA binding (3) .
HIF-1α, in contrast to constitutively expressed HIF-1β, has two oxygen responsive domains and is subjected to ubiquitination-dependent proteasomal degradation under normoxic conditions. One of these responsive domains is the oxygen-dependent degradation (ODD) domain (401-603 amino acids) that is involved in protein stability. Under normoxic conditions, the 564 th and/or 402 nd proline residues of HIF-1α become hydroxylated by HIF-1α-specific prolyl-4-hydroxylases (PHDs), which utilize molecular oxygen, α-ketoglutarate and HIF-1α as substrates, and vitamin C and Fe (II) as cofactors. E3 ubiquitin ligase, known as the von Hippel-Lindau (VHL) protein, interacts with the hydroxylated prolines of HIF-1α, leading to its ubiquitination and degradation. The second oxygen responsive domain is the C-terminal transactivation domain (C-TAD, 786-826 amino acids), which is also inhibited by oxygen. The 803 rd asparagine residue of HIF-1α is hydroxylated by a HIF-1α-specific asparaginyl hydroxylase named Factor-Inhibiting HIF-1 (FIH-1). This event prevents HIF-1α from recruiting its coactivator, cAMP-response element-binding protein (CBP) (4). Therefore, both stability and transactivation of HIF-1α are prevented by oxygen-dependent hydroxylation. Under hypoxic conditions, both prolyl-and asparaginyl-hydroxylation are inhibited, thereby stabilizing HIF-1α protein and enabling its transactivational activity.
The activation of HIF-1α promotes the progression of various cancers by increasing oxygen delivery to cells via angiogenesis and by activating glycolysis. However, beneficial effects are also attained for ischemic diseases such as stroke and myocardial infarction by inducing expression of VEGF and erythropoietin (EPO) (5) . These pathological characteristics indicate that an activator of HIF-1α could ameliorate ischemic disease, whereas an inhibitor could be used to prevent cancer.
We have identified small compounds that activate HIF-1α, such as clioquinol, SNAP ((±)-S-nitroso-N-acetylpenicillamine) and baicalein (6) (7) (8) . These compounds inhibit both asparaginyl hydroxylation and proline hydroxylation-dependent ubiquitination, leading to the accumulation of trans-active HIF-1α even in normoxic conditions. However, these compounds do not directly target HIF-1α; instead, they inhibit PHDs, ubiquitination and FIH-1.
In this study, we screened small peptides that directly interact with HIF-1α by using a yeast two-hybrid system. We found http://bmbreports.org P]-labeled double-stranded oligonucleotides containing HRE sequences as previously described (14) . The indicated amount of in vitro transcribed and translated HIF-1α (IVTT-HIF-1α) were pre-incubated with F29 peptide for 30 min at room temperature, followed by the addition of IVTT-HIF-1β. After 5 min, radio-labeled oligonucleotides (5 × 10 5 cpm) were incubated with the reaction mixture for 45 min at room temperature, and final mixtures were separated on 5% PAGE. Gels were dried and analyzed by autoradiography. RRL, unprogrammed rabbit reticulocyte lysates. a 16-mer peptide named F29 that specifically interacts with HIF-1α. Our results show that F29 increases the DNA-binding ability of HIF-1α, thus increasing the expression of its target gene, VEGF.
RESULTS AND DISCUSSION

Isolation of HIF-1α interacting peptide, F29
To find peptides that interact with HIF-1α, yeast two-hybrid screening was performed using the bHLH-PAS domain (13-344 amino acids) of human HIF-1α as bait, as well as a random peptide library (Clontech) with a 16 amino acid open reading frame conjugated with the transactivation domain of GAL4. The AH109 yeast strain was transformed first by pGBKT7-HIF-1α, which encodes the DNA-binding domain of GAL4 fused to human HIF-1α bHLH-PAS domain (13-344 amino acids), and second using a random peptide library. Since the bHLH-PAS domain (13-344 amino acids) has both dimerization and DNAbinding domains but no transactivation domain, the reporter gene is activated only when the bHLH-PAS domain interacts with its target peptide. We screened 1.34 × 10 7 independent clones and inoculated the resulting AH109 transformants on SD/-Trp/-Leu/-His plates, obtaining 660 colonies. To remove false-positives, His + colonies were streaked on SD/-Trp/-Leu/ -His/-Ade plates and incubated at 30 o C for 4 to 5 days. Fifteen of these colonies were identified as His + /Ade + positive and were thus streaked again on SD/-Trp/-Leu/-His/-Ade/X-α-gal plates. Finally, 7 blue-colored colonies were selected.
More than one plasmid can be replicated in yeast, and a selected yeast colony may have more than one kind of peptide (9) . Therefore, single plasmids from the 7 blue-colored His + phenotype, AH109 cells were retransformed with each of the isolated plasmids along with pGBKT7-HIF-1α, and then inoculated on an SD/-Trp/-Leu/-His/-Ade plate. Retransformed colonies were also cultured in liquid media and tested for β-galactosidase in order to evaluate the strength of the interaction between HIF-1α and peptides. We next selected a total of seven plasmids and analyzed their nucleotide sequences. We found only one peptide, named F29 (TQYGSSKIVQRGVLFA), that has 16 amino acids in the correct sequence followed by a stop codon (Fig. 1A) . http://bmbreports.org BMB reports ) were transfected with 100 ng of p(HRE)4-luc and 50 ng of β-galactosidase-encoding plasmid (pCHO110) using LipofectAMINE Plus reagent according to manufacturer's instructions (Invitrogen). Sixteen hr prior to harvest, cells were treated with synthesized peptides (TAT or TAT-F29) and/or CoCl2 as indicated. Luciferase assays were performed as previously described (14) . Values represent means and standard deviations of three independent experiments. (B) HepG2 cells were treated with the indicated amount of peptide and/or CoCl2 for 16 hr. The total RNA was isolated and mRNA level of VEGF was analyzed using the northern analysis method (14) . VEGF, vascular endothelial growth factor.
To confirm the interaction between HIF-1α and F29, 35 S-labeled HIF-1α (13-344 amino acids) was synthesized by in vitro transcription and translation and then incubated with biotinylated F29 peptide. We examined the interaction between HIF-1α and F29 by measuring 35 S-labeled HIF-1α captured by avidin-associated biotinylated F29 peptide. Compared to a control peptide, F29 interacts more strongly with HIF-1α (Fig. 1B) .
The fact that F29 interacts with the bHLH-PAS domain of HIF-1α, which mediates both dimerization and HRE-binding, suggests that the dimerization-dependent DNA-binding ability of HIF-1α can be altered. In vitro transcribed and translated HIF-1α and HIF-1β were incubated with labeled oligonucleotides containing HRE sequences in the presence of F29 peptide and then subjected to EMSA. The presence of both HIF-1α and β decreased the amount of HRE oligonucleotide in PAGE by creating a HRE/protein complex (arrowhead in Fig. 1C ). The result in Fig. 1C reveals that a low dosage of F29 does not inhibit HRE binding (left panel of Fig. 1C ). Instead, F29 at high dosages (50∼500 μM) increased the formation of the HRE/ HIF-1α/β complex (right panel of Fig. 1C ). This result shows that F29 facilitates the interaction of HIF-1α with HRE.
Effect of TAT-F29 peptide on hypoxia-induced gene expression
We investigated the effect of F29 peptide on the HIF-1-induced gene expression of VEGF (10) . We synthesized TAT-F29 peptide (YGRKKRRQRRR-YPYDVPDYA-TQYGSSKIVQRGVLFA) containing a F29 16-mer (TQYGSSKIVQRGVLFA) conjugated with the HA sequence (YPYDVPDYA) along with the protein transduction domain (PTD) of viral TAT protein (YGRKKRRQRRR). Eleven different PTD amino acid sequences are known to facilitate a fused peptide or protein capable of entering cells (11, 12) . The control peptide, TAT, contains PTD and the HA sequence without the F29 peptide. We transfected 293 cells with HRE-driven reporter plasmid (pHRE4-luc), followed by treatment with TAT-F29 or TAT peptide for 16 hr. Treatment with the non-hypoxic HIF-1α inducer CoCl2 (100 μM) increased expression of the HRE-driven luciferase gene. However, TAT-F29 failed to alter the expression level of HRE reporter genes in both normoxia and CoCl2-treated cells ( Fig. 2A) . To test the effect of TAT-F29 on the endogenous HIF-1α target gene, we treated HepG2 cells with TAT-F29 or TAT peptide for 16 hr, and then measured the mRNA level of VEGF by Northern blot analysis (Fig. 2B ). Treatment with CoCl2 (100 μM) increased the mRNA levels of http://bmbreports.org Luciferase assays were performed as previously described (14) . Values represent means and standard deviations of three independent experiments. (C, D) Cells were transfected with either an empty vector (EV) or pF29. The transfected cells were treated with hypoxia (0.1% O2) or 100 μM of CoCl2 for 16 hr. The mRNA of VEGF was visualized by exposure to X-ray film. VEGF, vascular endothelial growth factor; N, normoxia; C, CoCl2; H, hypoxia.
Fig. 4.
Effects of pF29 on HIF-1α protein stability. Human PC-3 cells were transfected with either an empty vector (EV) or pF29. The transfected cells were treated with hypoxia or CoCl2 for 6 hr. Whole cell lysates were separated on 8% SDS-PAGE. HIF-1α protein was detected by Western blot analysis using anti-human HIF-1α antibody (BD Biosciences) (14) . N, normoxia; C, CoCl2; H, hypoxia.
VEGF. However, TAT-F29 (∼5 μM) failed to cause any significant changes in the expression of VEGF (Fig. 2B) . In order to confirm the entry of TAT-F29 peptide into cells, we performed Western blots using HA antibody. We could not detect TAT-F29 peptide in treated cells most likely due to the molecular weight of TAT-F29 (4.32 κDa) being too small for detection by Western analysis (data not shown). Nevertheless, our finding (in Fig. 1C ) that more than 50 μM of F29 peptide is required for the enhancement of HRE/HIF-1α/β complex formation in vitro suggests that two or five μM of TAT-F29 is insufficient for the alteration of cellular HIF-1α activity. Our results imply that F29 interacts with HIF-1α with low affinity presumably, as more than 50 μM of F29 peptide is required for the function of HIF-1α to be affected.
Effect of pF29 on hypoxia-induced gene expression
Instead of a high dose of synthetic peptides, we expressed F29 in cells by transfecting a plasmid-encoding F29 peptide. Oligonucleotides corresponding to the amino acid sequence of the F29 peptide were subcloned into the pCMV-3 × FLAG vector and thusly named pF29. We transfected HepG2 cells with a HRE-driven luciferase reporter plasmid (pHRE4-luc) and pF29, as shown in Fig. 3A and B. Co-transfection of pF29 increases expression of the reporter genes in dose-dependent fashion in both normoxia and CoCl2-treated HepG2 cells (Fig.  3A, B) . F29 was not detected in pF29-transfected cells using FLAG antibody. Nevertheless, we conclude that the transfection of pF29 delivers more peptide to cells compared to direct treatment with TAT-F29. We also measured endogenous mRNA levels of VEGF in cells after transfection with pF29.
CoCl2 and hypoxia treatment increased the expression of VEGF (Fig. 3C, D) . The transfection of pF29 slightly increased the level of VEGF mRNA in both hypoxic and normoxic cells with a transfection efficiency of 50 to 70%. We therefore assumed that a certain population of cells was not transfected with pF29. For Northern blot analysis, we harvested total RNA without selecting pF29-transfected cells. Notably, the effects of pF29 may be less evident by Northern analysis than by reporter-gene analysis, since the expression of a reporter gene is only detected in cells transfected with the pF29 plasmid. Nevertheless, we observed that pF29 consistently increases the expression of VEGF in normoxic, hypoxic and CoCl2 treated cells.
Effect of pF29 on expression of HIF-1α
In order to test whether F29 increases the stability of HIF-1α protein, we measured the protein level of HIF-1α in PC-3 cells transfected with pF29. Western analysis showed that the transient transfection of pF29 instead slightly decreases the protein level of HIF-1α in normoxic and hypoxic cells (Fig. 4) . Our re-http://bmbreports.org BMB reports sults indicate that F29 binds to the bHLH-PAS domain of HIF-1α and increases its activity, but not its amount. Since the targets genes of HIF-1α, rather than HIF-1α itself, are involved in hypoxia-related diseases, it is implied that increased activity and not HIF-1α stability is significant for therapeutic applications. Using a yeast two-hybrid system, we produced the 16-mer peptide, F29 that interacts with the bHLH-PAS domain of HIF-1α. Our result showed that transient transfection of the F29-expressing plasmid increases expression of the co-transfected HRE-driven reporter gene and of the endogenous HIF-1α target gene, VEGF. In vitro assays showed thatF29 interacts with the bHLH-PAS domain of HIF-1α, facilitating the interaction of the HIF-1α/β heterodimer with HRE. This suggests that F29 increases expression of its target gene by increasing the DNA-binding ability of HIF-1α. F29 was synthesized conjugated to the PTD sequence (11 mer) of TAT protein, which facilitates entry of the fused peptide into cells. The conjugated peptide was then added to culture media in order to directly examine its effect on the cellular function of HIF-1α. Since the synthetic peptide was limited in amount and solubility, cells were treated with 5 μM of TAT-F29 at maximum concentration. TAT-F29 failed to increase expression of HRE-driven luciferase genes and of the endogenous VEGF gene at this dosage level. Therefore, our results show that the potency of F29 peptide is insufficient at a concentration of 5 μM at increasing the function of HIF-1α in vivo. In general, the inefficient delivery of peptide to target cells is considered a drawback. However, our results using F29-encoding plasmids suggest that F29 is a novel molecule that directly targets HIF-1α and increases its activity, despite its low efficacy. In addition, the fact that HIF-1α is present only in hypoxic tissues emphasizes the possibility that F29 can be an effective leading compound in the development of hypoxia-specific drugs that control ischemic diseases and cancer. The three-dimensional structure of the bHLH-PAS domain of HIF-1α has not yet been identified. Therefore, comparative structural analysis of F29 and HIF-1α will provide a rational drug-design strategy for improving the potency and efficacy of F29.
YC-1, Taxol and Geldanamycin act as inhibitors of HIF-1α by modulating upstream pathways involved in its activation (13) . Clioquinol is also an HIF-1α activator and leads to the accumulation of the trans-active form of HIF-1α by inhibiting both FIH-1 and HIF-1α ubiquitination (6) . Since these chemicals target upstream regulators instead of HIF-1α directly, we should be concerned with potential side effects. In summary, we provided a novel lead compound that directly targets HIF-1α instead of HIF-1α regulators.
MATERIALS AND METHODS
Cells and reagents
Human HepG2 hepatoma cells (ATCC HB-8065), human PC-3 prostate cancer cells (ATCC CRL-1435) and human 293 cells (ATCC CRL-1573) were purchased from the American Type Culture Collection (ATCC) and maintained as recommended. Cells were exposed to hypoxia (0.1% O2) using an anaerobic incubator (Model 1029, Forma Scientific, Inc.) or chemical hypoxic mimicker CoCl2 (Sigma Co.) (6) . The MATCHMAKER random peptide library (Cat# NL4000AA) and GAL4 two-hybrid system 3 (Cat# K1612-1) were purchased from Clontech (Takara Bio Inc., Palo Alto, CA, USA). All other chemicals were purchased from Sigma Co.
Plasmids and peptides
To construct the plasmids pGBKT7-HIF-1α and pcDNA3-HIF-1α, the bHLH-PAS domain (13-344 amino acids) of human HIF-1α (GenBank Accession No. U22431) was amplified by PCR (sense primer, 5'-CCAGGATCCAAATAAGTTCTGAACGT-CGAAAA-3'; antisense primer, 5'-CTCGGATCCTCAACCACT-CACAACGTAATTCAC-3'). The amplified fragment was inserted into either the pGBKT7 (Clontech) or pcDNA3 (Invitrogen, Carlsbad, CA) plasmid. To construct an F29-encoding plasmid, double-stranded oligonucleotides corresponding to the amino acids sequences of F29 (sense, 5'-AGCTTACGCAGT-ATGGGTCTTCGAAGATTGTGCAGCGGGGTGTGTTGTTTG-CTTAGG-3'; antisense, 5'-GATCCCTAAGCAAACAACACACC-CCGCTGCACAATCTTCGAAGACCCATACTGCGTA-3') were subcloned into the pCMV-3 × FLAG vector (Sigma Co.). The resulting plasmid was named pF29. The p(HRE)4-luc reporter plasmid contains four copies of the HRE of the erythropoietin gene (nucleotides 3449-3470) followed by the firefly luciferase gene (14) . Biotinylated F29 peptide (Biotin-TQYGSSKIVQRGVLFA), F29 peptide (TQYGSSKIVQRGVLFA), Trans-Activating Transcription (TAT)-conjugated HA peptide (YGRKKRRQRRR-YPYDVPDYA), and TAT-conjugated HA-tagged F29 peptide (YGRKKRRQRRR-YPYDVPDYA-TQYGSSKIVQRGVLFA) were synthesized by AnyGen Co. Ltd. (Kwangju, Korea).
Yeast two-hybrid screening for HIF-1α-interacting peptide
Yeast two-hybrid screening was performed using GAL4 two-hybrid system 3 (Clontech) and a MATCHMAKER random peptide library as described in the manufacturer's instructions (15) . The human HIF-1α bHLH-PAS domain was used as bait. Using the lithium acetate method, AH109 yeast strain was transformed with pGBKT7-HIF-1α, which encodes the DNAbinding domain of GAL4 fused to human HIF-1α bHLH-PAS domain (13-344 amino acids). The AH109 yeast strain is of the genotype MATα, trp1-901, leu2-3, ura3-52 and his3-200 and three reporters (HIS3, ADE2, and Mel1/lacZ). AH109 was transformed with pGBKT7-HIF-1α and inoculated on a SD/-Trp plate. Selected transformants were sequentially transformed with library plasmids encoding 16-residue random peptides fused to the GAL4 activation domain. This was followed by inoculation on a SD/-Trp/-Leu/-His plate. Selected colonies were further screened by inoculation onto two selection media, SD/-Trp/-Leu/-His/-Ade and SD/-Trp/-Leu/-His/-Ade/X-α-gal. The plasmid DNA was then isolated from selected yeast transformants. To retest the selected library plasmid, AH109 was re-http://bmbreports.org transformed with the library plasmid and pGBKT7-HIF-1α. The dual transformant extract was used for β-galactosidase assay to compare the strength of the interaction between HIF-1α and library peptide. Finally, nucleotide sequences of the selected plasmid were analyzed.
In vitro peptide-protein interaction assay
[ 35 S] methionine-labeled HIF-1α protein (13-344 amino acids) was synthesized using an in vitro transcription and translation kit according to the instructions of the manufacturer (Promega, Cat# L1170). Biotinylated peptide F29 was synthesized and dissolved in water (1 mg/ml); 10 μl of immobilized monomeric avidin (50% slurry) (Pierce, Cat# 20227) was pretreated with 1 mg of bovine serum albumin for 5 min at room temperature and then incubated with 10 μg of biotinylated peptide in NETN buffer for 60 min at 22 o C (16); immobilized avidin-associated peptide was washed three times with 1 ml of NETN buffer and then mixed with 10 μl of IVTT 35 S-labeled HIF-1α in NETN buffer with rotation at 4 o C for 2 hr. The resin was washed four times with 1 ml of NETN buffer; proteins were eluted in 3 × SDS sample buffer and analyzed by 10% SDS-PAGE and autoradiography. The relative value of band intensity was measured using Cyclone PhosphorImager (Packard Instruments, Meriden, CT, USA).
